Cargando…
Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report
INTRODUCTION: Castleman's disease is a rare lymphatic polyclonal disorder that is characterised by unicentric or multicentric lymph node hyperplasia and non-specific symptoms and signs including fever, asthenia, weight loss, enlarged liver and abnormally high blood levels of antibodies. CASE PR...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292733/ https://www.ncbi.nlm.nih.gov/pubmed/18387191 http://dx.doi.org/10.1186/1752-1947-2-99 |
_version_ | 1782152521414868992 |
---|---|
author | Pelosi, Ettore Skanjeti, Andrea Cistaro, Angelina Arena, Vincenzo |
author_facet | Pelosi, Ettore Skanjeti, Andrea Cistaro, Angelina Arena, Vincenzo |
author_sort | Pelosi, Ettore |
collection | PubMed |
description | INTRODUCTION: Castleman's disease is a rare lymphatic polyclonal disorder that is characterised by unicentric or multicentric lymph node hyperplasia and non-specific symptoms and signs including fever, asthenia, weight loss, enlarged liver and abnormally high blood levels of antibodies. CASE PRESENTATION: We present the case of a 74-year-old man with Castleman's disease. The disease was detected with a contrast-enhanced computed tomography (CT) scan and a fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT study; diagnosis was made with histopathology. After treatment with surgical excision followed by chemotherapy, the disease response was evaluated using both diagnostic techniques. However, only the PET study was able to identify the spread of the disease to the abdominal lymph nodes, which were both enlarged and normal size, and, after treatment, to evaluate the disease response. CONCLUSION: Based on the results of previous case reports and on those of the present study, it seems that Castleman's disease has a high glucose metabolic activity. Therefore, the use of PET can be considered appropriate in order to stage or restage the disease and to evaluate the response of the disease to treatment. |
format | Text |
id | pubmed-2292733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22927332008-04-12 Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report Pelosi, Ettore Skanjeti, Andrea Cistaro, Angelina Arena, Vincenzo J Med Case Reports Case Report INTRODUCTION: Castleman's disease is a rare lymphatic polyclonal disorder that is characterised by unicentric or multicentric lymph node hyperplasia and non-specific symptoms and signs including fever, asthenia, weight loss, enlarged liver and abnormally high blood levels of antibodies. CASE PRESENTATION: We present the case of a 74-year-old man with Castleman's disease. The disease was detected with a contrast-enhanced computed tomography (CT) scan and a fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT study; diagnosis was made with histopathology. After treatment with surgical excision followed by chemotherapy, the disease response was evaluated using both diagnostic techniques. However, only the PET study was able to identify the spread of the disease to the abdominal lymph nodes, which were both enlarged and normal size, and, after treatment, to evaluate the disease response. CONCLUSION: Based on the results of previous case reports and on those of the present study, it seems that Castleman's disease has a high glucose metabolic activity. Therefore, the use of PET can be considered appropriate in order to stage or restage the disease and to evaluate the response of the disease to treatment. BioMed Central 2008-04-03 /pmc/articles/PMC2292733/ /pubmed/18387191 http://dx.doi.org/10.1186/1752-1947-2-99 Text en Copyright © 2008 Pelosi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Pelosi, Ettore Skanjeti, Andrea Cistaro, Angelina Arena, Vincenzo Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report |
title | Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report |
title_full | Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report |
title_fullStr | Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report |
title_full_unstemmed | Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report |
title_short | Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report |
title_sort | fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with castleman's disease: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292733/ https://www.ncbi.nlm.nih.gov/pubmed/18387191 http://dx.doi.org/10.1186/1752-1947-2-99 |
work_keys_str_mv | AT pelosiettore fluorodeoxyglucosepositronemissiontomographycomputedtomographyinthestagingandevaluationoftreatmentresponseinapatientwithcastlemansdiseaseacasereport AT skanjetiandrea fluorodeoxyglucosepositronemissiontomographycomputedtomographyinthestagingandevaluationoftreatmentresponseinapatientwithcastlemansdiseaseacasereport AT cistaroangelina fluorodeoxyglucosepositronemissiontomographycomputedtomographyinthestagingandevaluationoftreatmentresponseinapatientwithcastlemansdiseaseacasereport AT arenavincenzo fluorodeoxyglucosepositronemissiontomographycomputedtomographyinthestagingandevaluationoftreatmentresponseinapatientwithcastlemansdiseaseacasereport |